Rhythm Pharmaceuticals Q2 2025 Earnings Report

Rhythm Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.64
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Rhythm Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $43.72 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rhythm Pharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 5, 2025
• Conference Call Time: 8:00AM ET

Rhythm Pharmaceuticals (NASDAQ:RYTM) (NASDAQ: RYTM) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic and endocrine-related disorders of obesity. The company’s lead product, setmelanotide (IMCIVREE), is an FDA-approved melanocortin-4 receptor (MC4R) agonist designed to address the underlying genetic causes of obesity in patients with specific genetic deficiencies, including POMC, PCSK1 and LEPR deficiencies. Beyond its approved indications, Rhythm is actively pursuing additional clinical trials to expand the use of setmelanotide to other rare genetic obesity disorders and exploring its potential in common obesity populations. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals has established a robust pipeline aimed at transforming the treatment landscape for patients affected by rare obesity disorders. The company’s research and development efforts concentrate on the melanocortin pathway, which plays a central role in energy homeostasis and appetite regulation. Rhythm’s approach combines targeted molecular design with precision medicine, enabling tailored therapies that directly address specific genetic mutations. Its R&D infrastructure includes state-of-the-art laboratories and strategic collaborations with academic institutions and patient advocacy groups worldwide. Rhythm Pharmaceuticals serves a global patient community through a network of specialty pharmacies, healthcare providers and patient support programs. While its primary market is in the United States, the company is pursuing international regulatory approvals and partnerships to extend its reach into Europe and other key markets. Rhythm’s patient-centric initiatives include education, genetic testing support and financial assistance programs aimed at improving access to treatment for individuals with pathogenic genetic variants. Under the leadership of Chief Executive Officer David Meeker, Rhythm has grown its management team and board of directors with experienced professionals in biotechnology, regulatory affairs and commercial strategy. Meeker, previously a key executive at Amicus Therapeutics, brings extensive expertise in rare disease drug development and global commercialization. The company’s leadership team continues to expand as Rhythm advances its clinical programs and prepares for broader market launches.